Patent · US Active

Biological products

US8895714B2 · kind B2 · utility

2Cited by

23References

19Claims

0Family size

Assignee

UCB PHARMA S.A. · BE

Inventors

Simon Peter Tickle · Slough, GB
Heather Margaret Ladyman · Slough, GB

Key dates

Filing date	Mar 16, 2011
Grant date	Nov 25, 2014
Priority date	—
Expiry date	Apr 13, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q1/686
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.